Participated · Series B · Sep 2023

Awak Technologies is a Singapore-based patient-centric medical technology company led by CEO Suresha Venkataraya. Its core product is an ultra-portable peritoneal dialysis system that enables kidney disease patients to undergo dialysis at home or on the go. The company’s patented technologies regenerate and reconstitute waste dialysis fluid into usable fluid, reducing the amount of dialysis fluid needed by up to 90% and enabling miniaturisation of the machine to fit into a small carry bag. Awak plans to use the recent funding to complete an ongoing human pre-pivotal clinical trial, further enhance its products and portfolio, and advance toward a US-based pivotal trial and eventual US launch. The company has offices in Burbank, California and Bengaluru, India. The Series B financing (over USD$20M) supports these clinical and commercialisation efforts. AWAK Technologies develops the AWAK PD, a wearable, ultra‑portable sorbent‑based peritoneal dialysis device that removes uremic toxins from spent dialysate and reconstitutes used fluid into fresh fluid in real time. The device is lightweight (a couple of kilograms), designed for patient self‑administration without medical supervision and aims to eliminate dependence on large dialysate volumes, continuous water supply and costly water treatment. AWAK completed a first‑in‑human study in October 2018 with no serious adverse events and demonstrated effective waste removal, and the device has received FDA Breakthrough Device Designation. Proceeds from the recent financing will be used to complete a pivotal clinical trial, strengthen R&D, and prepare for manufacturing and commercialisation, with AWAK expecting to initiate a pivotal study in the next 12–18 months while engaging global regulators. The company is headquartered in Singapore with an office in Burbank, California. Financially, AWAK closed an oversubscribed US$40M financing in 2019 — the largest medtech fundraise in Singapore and among the largest in Southeast Asia — bringing total funding since inception to more than US$60M. AWAK Technologies is a Singapore medtech startup focused on developing solutions for patients with end-stage renal disease. Its core work centers on medical technologies aimed at treating or managing end-stage renal failure. The company recently secured an $11.2 million investment led by Accuron MedTech. Accuron MedTech is a division of Accuron Technologies Limited, a wholly‑owned subsidiary of Temasek Holdings. The article does not disclose the financing instrument, participation of additional investors, past rounds, revenues, or other operating metrics. The reported funding represents institutional backing from a Temasek‑linked investor as AWAK advances its medtech efforts.

Led · Series C · Nov 2022

SonoMotion is a clinical-stage medical technology company focused on non-invasive, ultrasound-based treatments for kidney stones. Its two main products, Break Wave and Stone Clear, are designed to fragment and clear stones using low-pressure ultrasound while patients remain fully awake, eliminating the need for anesthesia and a surgical suite. Stone Clear secured FDA 510(k) de novo clearance in October 2024, and Break Wave has now finished enrollment in a 64-patient pivotal SOUND trial that will support an upcoming 510(k) submission. Together, the devices share a common platform aimed at offering a complete, first-line solution for stone management in office or clinic settings. Kidney stones affect roughly one in ten Americans and drive more than 750,000 procedures annually, representing a $10 billion U.S. market opportunity. Venture capital–backed SonoMotion continues to advance its regulatory and commercial roadmap, recently bolstered by non-dilutive NIH funding to reach key milestones.

Led · Series A · Jan 2021

Devicare develops Lit-Control, a non-surgical solution for kidney stones that pairs a urine pH measuring device with an application to adjust nutraceutical dosing. The device measures patients' urinary pH and sends data to the app, enabling telemetric management and dose adjustments of nutraceuticals sold under the Lit-Control brand. The company already commercializes its nutraceuticals in Spain, has an agreement with Diem Labs to explore the U.S. market, and expects to start selling the pH meter around 2022. In 2020 Devicare reported €1 million in revenue and expected 50% growth in the following year. Proceeds from the new financing will be used to refine the Lit-Control software. Devicare is based at the Parc de Recerca de la UAB in Cerdanyola, was founded in 2012, and has raised €12 million in public and private capital since inception. Devicare is a Cerdanyola del Vallès, Barcelona, Spain–based medical device company specializing in innovative home-care solutions for chronic patients. It is developing a patented sensor technology to measure biometrics in breath and body fluids, including blood, sweat, saliva and urine, for disease prevention and treatment. The company currently offers two product lines: Lit-Control for prevention and self-management of recurrent urinary diseases, and Tao-Control for self-management of patients taking anticoagulants. Devicare has signed a €2m participative loan from the Innova Global line by Avançsa, with an option to convert the investment into Series A stock in the mid-term. Proceeds will fund the strategic development and validation plan of new medical solutions under a Remote Patient Monitoring concept and the corresponding clinical studies and trials. The company intends to use these results to support expansion throughout European and North American markets. Devicare develops and remotely manages medical devices for the home care of chronic patients. It currently markets two Remote Patient Monitoring (RPM) products: Lit-Control, which prevents and controls recurrent urological diseases via urinary pH monitoring, and Tao-Control, which helps control INR levels for patients on oral anticoagulants. These solutions are built under the RPM concept to enable patients to actively participate in monitoring their disease. The products are placed on the market through agreements with pharmaceutical companies. The company received a €133K participation loan to consolidate sales of its in-home self-management medical products. Devicare develops innovative medical devices targeting chronic home care patients, operating under a Remote Patient Monitoring (RPM) model. Its product lines include Lit-Control® for prevention and self-management of recurring urinary diseases and Tao-Control® for self-management of patients on oral anticoagulants. The company is led by founder and CEO Rosendo Garganta and Xavier Peris, sales and marketing director. Devicare intends to use recent funding to consolidate the launch of clinical studies of its product lines in the Spanish market. In 2017 the company recorded €1.1m in revenue and employs a staff of 20 professionals. To date the company has raised a total of €4.5m.

Led · Series A · Oct 2020

ABM Respiratory Care develops intelligent, clinically differentiated respiratory care solutions for use inside and outside the hospital. Its latest product, BiWaze® Clear, is a compact, battery-operated airway clearance system that combines lung expansion, high-frequency oscillations, and integrated aerosol delivery in a portable closed-loop dual-lumen circuit. The device is designed to enhance aerosol deposition deep in the lungs, improve mucus clearance, and shorten therapy time for home and hospital use. ABMRC plans to scale U.S. sales, invest in clinical research, and enhance patient engagement and digital health capabilities to support commercialization. The company recently completed an oversubscribed Series B financing, strengthening its financial position to accelerate market rollout of BiWaze® Clear. ABMRC is headquartered in Eagan, Minn. ABM Respiratory Care is a Singapore-based medical device company focused on developing novel integrated airway clearance and ventilation solutions. The company develops intelligent, clinically differentiated and innovative respiratory care products intended to help people breathe better inside and outside the hospital. ABM is led by CEO Vinay Joshi. The company raised US$10.3M in a Series A funding round to support its growth. The funding will help ABM advance its U.S. commercialization plans. ABM also announced the appointment of Peter H. Soderberg as Chairman of the company’s Board of Directors.

Led · Series A · Dec 2017

Advent Access is a Singapore-based medtech spin-off from A*STAR developing the patented av-Guardian™, a device-guided needling platform that engineers a high-quality tissue track to enable reliable and less-painful vascular access to arteriovenous fistulas used by dialysis patients. The av-Guardian™ pioneers a “guardian guide-door” concept that is non-invasive to the vessel, intended to reduce wear and tear on patients' veins and lower rates of hospitalization and surgery. The company has worked with ETPL, A*STAR’s commercialization arm, on productization and clinical validation. Led by founder and CEO Peh Ruey Feng, Advent Access plans to use the financing to advance development and commercialization of the av-Guardian™. Management targets a filing for CE mark registration within the next 18 months. Financially, the company closed a S$2.6m pre-Series A financing to support these activities.